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Background: The incidence and associated factors of loose seed migration were investigated in cohort 1 of the
Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS).
Methods: The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent iodine-125
seed implantation (PI) and 519 patients who underwent PI combined with external beam radiation therapy (PI + EBRT).
The presence or absence of seed migration to the chest and abdominal/pelvic region was determined.
Results: Seed migration was observed in 22.7 % of PI group patients and 18.1 % of PI + EBRT group patients (p = 0.0276).
Migration to the lungs and abdominal/pelvic region was observed in 14.6 % and 11.1 % of the patients in the PI group,
and 11.2 % and 8.5 % of the patients in the PI + EBRT group, respectively. In the PI group, the number of implanted seeds
was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the
volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) or the minimal dose received by 90 % of the
prostate volume (D90 [Gy]) between the patients with and without seed migration.
Conclusions: This prospective cohort study investigating the largest number of past cases showed no difference in D90
(Gy) or V100 (%) between seed migration or the absence thereof in both the PI group and PI + EBRT group.
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Transperineal permanent iodine-125 seed implantation
(PI) for prostate cancer is widely accepted as a standard
procedure for treating early-stage prostate cancer [1, 2].
It has shown favorable treatment outcomes [3, 4]. In
Japan, treatment with iodine-125 (I-125) was introduced
in July 2003 and is widely accepted [5, 6].
Seed migration is a well-known adverse event associ-
ated with PI. The seed migration incidence is reported
to be 1.7–69.4 % [7–9]. There is a well-developed venous
plexus around the prostate, and seeds are implanted
near or within the veins. Thus, the seeds enter blood
vessels and are transported by blood flow, which is con-
sidered to be the mechanism causing seed migration
[10–13]. Various locations have been reported as sites of
seed migration, including the lungs, abdomen, pelvic
cavity, heart [14], vertebral venous plexus [15], kidneys
[16], liver [17], and testicular veins [18]. As for the seed
migration incidence, there are many reports of studies
concerning only migration to the lungs, whereas only a
few reports describe studies including migration to sites
other than the lungs [9].
There is no report that comparatively investigates the
incidence of seed migration by dividing between a PI
group and PI combined with external beam radiation
therapy (PI + EBRT) group. Past reports also had a small
sample size of 20 to 495 cases that were investigated for
seed migration, and nearly all reports came from only a
single facility. [8–13, 19–26].
Our study is a nationwide multi-institutional cohort
study called the Japanese Prostate Cancer Outcome
Study of Permanent Iodine-125 Seed Implantation
(J-POPS; NCT00534196) [5]. We report the results of
our investigation of the incidence of seed migration with
loose seeds by using J-POPS data, and of the factors
associated with the occurrence of migration.
The present study is the world's first reported pro-
spective cohort study on I-125 loose seed migration, and
investigates a record number of cases.
Methods
J-POPS study
The J-POPS is a prospective cohort study evaluating the
clinical significance of PI in Japan [5]. All enrolled pa-
tients had been diagnosed with histologically proven and
clinically localized prostate cancer. The indications and
contraindications for treatment were determined accord-
ing to the American Brachytherapy Society (ABS) rec-
ommendations [27]. Of 2354 patients enrolled in cohort
1 from 46 facilities between July 2005 and June 2007, we
included 2160 patients, excluding 2 duplicate enroll-
ments, 12 previously untreated patients, 11 ineligible
patients, 34 patients without data on the presence or ab-
sence of seed migration, and 145 patients who did notundergo chest radiography. Moreover, patients in whom
seeds were shed into the seminal vesicles or bladder
were not included in the group of patients with seed
migration.
This study was approved by the foundation for Bio-
chemical Research and Innovation. The ethical review
committee of the Translational Research Informatics
Center (TRI); the Institutional Review Boards of all par-
ticipating facilities approved this study.
The treatment technique and recommended radiation
field and dosimetry have been described previously [5].
Briefly, according to the American Brachytherapy Society
recommendations, preplanning was undertaken using
transrectal ultrasonography. The clinical target volume
(CTV) was determined from gross target volume that was
defined as the prostate volume visualized on ultrasonog-
raphy with an added treatment margin of 3-5 mm in all
directions, except for <2 mm in the posterior direction.
The CTV for PI and PI + EBRT was same. In PI cases, the
prescribed radiation doses were set so that the values of
the minimal dose received by 90 % of the prostate volume
(D90) would be 144 Gy for the CTV. In the cases of PI +
EBRT, the prescribed radiation doses were set so that the
D90 values would be 100–110 Gy for the CTV, and the
prescribed radiation doses in EBRT were set at 40–50 Gy,
which was recommended to be delivered in 20–25 frac-
tions. Post-planning was undertaken using CT scanning
approximately one month after treatment. For pre- and
post-planning, Interplant version 3.0 to 3.4, manufactured
by CMS, or VariSeed version 7.0 to 7.1, manufactured by
VARIAN, software was used. I-125 seeds were loose seeds,
and OncoSeed (Nihon Mediphysics©) or Brachy source
(Bird©) was used and implanted using a Mick applicator
(Mick TP 200 Mick Radio-Nuclear Instruments) in all
patients [5].
Methods to evaluate seed migration
Seed migration was checked during a period from the
following day to three months after PI. The presence or
absence of migration to the lungs was checked by chest
radiography (with a posterior-anterior [PA] view alone
or PA and lateral [PA + lateral] views), and the presence
or absence of migration to the abdomen or pelvis was
checked with plain abdominal radiography except for
only one institution (35 cases) checked with plain abdo-
minopelvic CT. Patients were divided into the PI group
(1641 patients) and the PI + EBRT group (519 patients)
for assessment.
Toxicity scoring and follow-up schedule
In order to grade adverse events associated with the rec-
tum and urination conditions, the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 3.0 were used. Adverse events
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the highest grade during this period was used for ana-
lysis [5].
Statistical analyses
Wilcoxon signed-rank test and chi-square analysis were
used to determine the strength of the relationships be-
tween seed migration and clinical treatment parameters.
A 0.05 level of statistical significance and confidence in-
tervals with 95 % probability were set. Statistical analyses
were performed using SAS statistical software (version
9.3, SAS Institute Inc., Cary, NS, USA). All statistical
analyses were performed at the TRI [5].
Ethical considerations
This study was reviewed by the ethical review committee
of each participating facility and conducted after written
consent was obtained from patients [5].
Results
Methods and timeline of checking of seed migration
The methods used to evaluate seed migration were chest
radiography with the PA view plus plain abdominal radi-
ography in 1283 patients (59.4 %), chest radiography
with the PA + lateral views plus plain abdominal radiog-
raphy in 834 patients (38.6 %), and chest radiography
with the PA view plus abdominal CT in 43 patients
(2.0 %). The timeline of checking for seed migration was
the day after implantation in 244 patients (11.3 %), one
month after implantation in 1276 patients (59.0 %), and
three months after implantation in 640 patients (29.6 %).
Incidence and sites of seed migration
Table 1 shows the patient characteristics stratified by the
treatment strategies and the presence or absence of seed
migration.
Out of all 2160 patients, 466 (21.6 %) showed seed mi-
gration. It was observed in 22.7 % (372/1641) of patients
in the PI group and 18.1 % (94/519) of patients in the
PI + EBRT group. Seed migration incidence in the PI
group was significantly higher than that in the PI +
EBRT group (p = 0.0276). Among patients with seed mi-
gration, the mean of migrating seeds per patient was 1.6
seeds (range, 1–9 seeds) in the PI group and 1.5 seeds
(range, 1–5 seeds) in the PI + EBRT group. The number
of migrating seeds was two seeds or less in 87.6 % in PI
group and 86.2 % in PI + EBRT group. Migration to the
lungs was observed in 14.6 % (240/1641) of PI group pa-
tients and 11.2 % (58/519) of PI + EBRT group patients.
Moreover, migration to sites other than the lungs was
observed in 11.1 % (182/1641) and 8.5 % (44/519) in the
PI and PI + EBRT groups, respectively (Table 2).
The proportions of migrating seeds out of the total
number of implanted seeds were 0.49 % in the PI group(120822 seeds implanted in total) and 0.53 % in the PI +
EBRT group (26887 seeds implanted in total).
Within the PI group, the prostate volume (p = 0.0046)
and the number of implanted seeds (p < 0.0001) were
significantly larger in patients with seed migration than
in those without seed migration (Table 1).
The Japanese national guideline recommends that
total administered radionuclide activity be kept below
1300 MBq. Therefore, we had to reduce the prostate
volume to around 30 cc with neoadjuvant androgen
deprivation therapy (ADT) in case of PI monotherapy
[6]. We presume that those may have been the reasons
why the rate of patients treated with ADT was higher
in the PI group than in the PI + EBRT group (Table 1).
When patients with seed migration were divided into
those with seed migration confirmed on Day 1 and those
with seed migration confirmed during a period from one
to three months after implantation to assess the seed mi-
gration incidence, no significant difference was observed
in either the PI or PI + EBRT group (Table 1).Impact on radiation doses
In the PI group, no significant difference in the volume
of the prostate receiving 100 % of the prescribed dose
(V100 [%]) and D90 (Gy) values was observed between
patients with and without seed migration (p = 0.7332
and p = 0.5866, respectively), whereas the values of
volume of the prostate receiving 150 % of the pre-
scribed dose (V150 [%]), the minimal dose received
by 90 % of the urethral volume (UD90 [Gy]) and the
minimal dose received by 5 % of the urethral volume
(UD5 [Gy]) were significantly lower in patients with
seed migration (p = 0.0184, p = 0.0258 and p = 0.0371,
respectively). On the other hand, the PI + EBRT group
showed no significant difference in these prescribed
doses between patients with and without seed migra-
tion (Table 3). When the D90 (Gy) and V100 (%)
values were analyzed by dividing patients in both the
PI and PI + EBRT groups into three groups without
seed migration, with one migrating seed, and with
two or more migrating seeds, the values were signifi-
cantly lower in the group with two or more migrating
seeds compared to the group without seed migration
(Fig. 1).Planning and implant methods
Analysis according to planning methods revealed that,
within the PI group, the seed migration incidence was
significantly lower in patients receiving preplanning than
in those receiving other planning methods (preplanning
plus intraoperative planning). According to implantation
methods, no significant difference was observed in either
the PI or the PI + EBRT group (Table 1).
Table 1 Patient characteristics stratified according to the seed migration and treatment methods
PI PI + EBRT
Migration (−) Migration (+) p* Migration (−) Migration (+) p*
(n = 1269) (n = 372) (n = 425) (n = 94)
Age: mean (median) 68.0 (69.0) 67.4 (68.0) 0.1257 69.0 (70.0) 68.4 (69.0) 0.3808
Range 45-89 51-84 52-88 53-82
PSA (ng/mL): mean (median) 7.1 (6.4) 7.2 (6.4) 0.9354 10.7 (9.3) 10.8 (10.4) 0.7603
Range 1.6-41.8 2.0-33.0 1.9-42.0 3.6-27.2
BMI: mean (median) 23.6 (23.4) 23.7 (23.7) 0.1524 23.5 (23.4) 23.5 (23.3) 0.8588
Range 14.7-32.8 17.9-32.1 15.5-35.7 17.3-29.7
Prostate volume (mL)
Mean (median) 26.2 (25.5) 27.5 (26.5) 0.0046 24.1 (23.4) 25.1 (24.1) 0.2927
Range 7.3-71.0 10.4-56.9 7.0-61.9 11.0-60.9
Number of seeds
Mean (median) 72.6 (72.0) 77.4 (75.0) <0.0001 51.5 (50.0) 53.2 (50.5) 0.1044
Range 34-120 26-120 25-85 35-85
Number of migrated seeds
Mean (median) - 1.6 (1.0) - 1.5 (1.0)
Range - 1-9 - 1-5
Number of needles
Mean (median) 22.9 (22.0) 23.3 (23.0) 0.1913 18.1 (17.0) 18.4 (18.0) 0.3142
Range 10-45 12-41 9-36 11-32
Planning methods
Preplanning 320 60 0.1483 59 11 0.7385
Preplanning + intraoperative 949 312 366 83
Loading methods
Peripheral loading 229 56 0.3308 35 12 0.2408
Modified peripheral loading 1033 313 384 82
Modified uniform loading 7 3 6 -
Androgen deprivation therapy
Yes 699 231 0.0174 117 22 0.4429
No 569 141 308 72
Unknown 1 - - -
Clinical T stage
T1 965 302 0.1329 252 48 0.2662
T2 295 70 161 42
T3 2 - 12 4
Unknown 7 - - -
Gleason score
6 or less 873 262 0.5907 62 23 0.0028
7 384 108 312 52
8 or more 10 1 51 19
Unknown 2 1 - -
Risk classification (D’Amico)
Low 733 220 0.9139 9 4 0.0419
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Table 1 Patient characteristics stratified according to the seed migration and treatment methods (Continued)
Intermediate 505 146 334 63
High 17 4 82 27
Unknown 14 2 - -
Period of checking for migration
Day 1 164 42 0.4247 29 9 0.3806
1-3 months 1105 330 396 85
*: Wilcoxon signed test for qualitative variables, Fisher’s Exact for quantitative variables
PI = permanent iodine-125 seed implantation; PI+EBRT = PI combined with external beam radiation therapy; PSA = prostate specific antigen; BMI = body
mass index
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radiography
When patients were divided into those undergoing chest
radiography with the PA view alone and those with the
PA + lateral views for comparison, the PI group showed
that the incidence of seed migration to the lungs wasTable 2 Location and number of migrated seeds stratified
according to treatment methods
PI (%) PI + EBRT (%) p*
Migration
Yes 372 (22.7) 94 (18.1) 0.0276
No 1269 (77.3) 425 (81.9)
Site of migration
Lung 184 (49.5) 47 (50.0)
Lung + pelvis 48 (12.9) 10 (10.6)
Lung + abdomen 5 (1.3) 1 (1.1)
Lung + abdomen + pelvis 2 (0.5) -
Lung + others 1 (0.3) -
Pelvis 115 (30.9) 30 (31.9)
Abdomen 8 (2.2) 2 (2.1)
Abdomen + pelvis 1 (0.3) -
Spinal venous plexus - 1 (1.1)
Thigh 2 (0.5) -
Unknown 6 (1.6) 3 (3.2)
Number of migrated seeds
1 242 (65.1) 60 (65.2)
2 84 (22.6) 21 (22.8)
3 25 (6.7) 8 (8.7)
4 9 (2.4) 2 (2.2)
5 5 (1.3) 1 (1.1)
6 3 (0.8) -
7 3 (0.8) -
8 - -
9 1 (0.3) -
*: Chi square test
PI = permanent iodine-125 seed implantation; PI+EBRT = PI combined with
external beam radiation therapyhigher in patients undergoing chest radiography with the
PA + lateral views than in those undergoing chest radiog-
raphy with the PA view alone (p = 0.0133) (Fig. 2).
Seed migration incidence stratified by the time of study
enrollment
When the seed migration incidence was compared by
dividing the two-year study enrollment period into three
phases of eight months (early, intermediate, and late),
the PI group showed that the incidence was significantly
lower in the intermediate and late phases than in the
early phase (p = 0.0224 and p = 0.0004). In the PI + EBRT
group, no significant difference was observed (Fig. 3).
Adverse events
The adverse events associated with the rectum and urin-
ation (NCI-CTCAE version 7.0) were divided into those
below Grade 2 and those with Grade 2 or above for
comparison. During the three years of the follow-up
period, neither the PI nor PI + EBRT group showed any
significant difference in the grades of adverse events be-
tween patients with and without seed migration.
Discussion
Around the prostate, there is a well-developed venous
plexus. It is thought that seed migration occurs because
seeds enter the veins and are transported by blood flow
[12, 19]. The reported causes for seeds to enter the veins
include direct implantation of seeds in the veins [19], an
effect of intraabdominal pressure, posture, breathing,
gravity, pubic arch interference, oblique needle insertion,
number of seeds implanted, number of needles that
induces seeds implanted near the veins to enter the
veins [9, 18, 24, 28, 29], and edema occurring after
implantation [8]. There are many reports describing
that, especially when seeds are implanted in the
extracapsular area or at the level inferior to the apex
of the prostate, the seed migration incidence is high
[12, 19]. However, there are also reports that implant-
ation in the extracapsular area does not elevate the
seed migration incidence [10, 30].
Table 3 Dosimetric comparison of migration or no migration
PI PI + EBRT
Migration (−) Migration (+) p* Migration (−) Migration (+) p*
(n = 1269) (n = 372) (n = 425) (n = 94)
D90 (Gy)
Mean (median) 161.1 (160.9) 160.7 (159.8) 0.5866 119.9 (120.5) 117.7 (119.2) 0.2627
Range 78.0-231.9 86.4-223.7 60.2-191.6 74.3-161.4
V100 (%)
Mean (median) 93.7 (94.8) 93.5 (94.9) 0.7332 94.9 (96.2) 94.1 (95.9) 0.2491
Range 63.6-100.0 56.3-100.0 56.5-100.0 68.3-99.8
V150 (%)
Mean (median) 62.6 (63.5) 60.7 (60.7) 0.0184 63.6 (64.6) 60.9 (61.1) 0.0731
Range 20.8-94.6 18.4-91.6 16.3-90.7 30.3-87.0
UD90 (Gy)
Mean (median) 141.7 (142.5) 138.2 (136.1) 0.0258 110.3 (111.1) 106.9 (104.7) 0.1019
Range 7.9-336.5 15.7-255.3 40.0-180.0 43.5-170.4
UD5 (Gy)
Mean (median) 228.6 (225.2) 222.4 (218.7) 0.0371 169.0 (161.5) 162.6 (160.2) 0.1570
Range 119.0-427.0 125.9-338.2 97.6-338.4 102.0-251.6
*: Wilcoxon signed test for qualitative variable
D90 = minimal dose received by 90 % of the prostate volume; V100 = volume of the prostate receiving 100 % of the prescribed dose
V150 = volume of the prostate receiving 150 % of the prescribed dose; UD90 = the minimal dose received by 90 % of the urethral volume
UD5 = the minimal dose received by 5 % of the urethral volume; PI = permanent iodine-125 seed implantation
PI+EBRT = PI combined with external beam radiation therapy
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Although the transfer of seeds out of the prostate is re-
ferred to as seed migration, only the transfer of seeds to
the lung is regarded as seed migration in many cases. In
the present study, seed migration was defined as “an
event in which seeds enter a blood vessel and are trans-
ported out of the prostate by blood flow.” Thus, patients
in whom seeds were shed into the seminal vesicles or
bladder were not included in the group of patients with
seed migration. In some of the past reports, movement
of seeds within the seminal vesicles and the prostate was
also defined as seed migration [20, 31]. Because the defi-
nitions vary among reports, the definitions should be
checked before making any comparisons of the seed mi-
gration incidence.
Seed migration incidence
The seed migration incidence after PI using loose seeds
is reported to range from 1.7 % to 69.4 % [8–13, 19–26]
(Table 4). As for the seed migration incidence, there are
many reports of studies concerning only migration to
the lungs, but only a few reports have included migra-
tion to sites other than the lungs [9, 20, 29]. The inci-
dence of seed migration to the lungs alone is reported to
be from 1.7–55 %, and that of migration to sites other
than the lungs is reported to range from 5.4–7.9 %
(Table 4). When migration to the lungs is checked bychest radiography with the PA view alone, it has been re-
ported that migration may be overlooked in 10–15 % of
cases [10], and that seeds migrating to the vicinity of the
diaphragm may be overlooked [19].
In our study, the overall seed migration incidence was
21.6 % (PI: 22.7 %, PI + EBRT: 18.1 %); the incidence of
seed migration to the lung was 13.8 % (PI: 14.6 %, PI +
EBRT: 11.2 %) and the incidence of seed migration to
site other than lungs was 10.5 % (PI: 11.1 %, PI + EBRT:
8.5 %). These rates were comparable to those described
in previous reports (Table 4). Our study included 1326
patients (61.4 %) who underwent chest radiography with
the PA view alone and 834 patients (38.4 %) who under-
went chest radiography with the PA + lateral views. The
rate of detection of seed migration to the lungs by chest
radiography with the PA + lateral views was higher than
that by chest radiography with the PA view alone (Fig. 2);
in patients undergoing chest radiography with the PA
view alone, the incidence of seed migration to the lung
might have been underestimated.
Moreover, in cases of seed migration to the heart,
chest radiography may not be able to detect migrating
seeds because of the heart rate [32]. Thus, CT is report-
edly useful for identifying the accurate location of seeds
migrating to the chest [14, 33]. However, performing chest
CT for confirming migrations may increase the excess ra-
diation exposure. Therefore, performing additional chest
Fig. 1 Dosimetric comparison of migration numbers. a: D90 (Gy), b: V100 (%) D90 (Gy) = minimal dose received by 90 % of the prostate volume;
V100 (%) = volume of the prostate receiving 100 % of the prescribed dose; PI = permanent iodine-125 seed implantation; PI + EBRT = PI combined
with external beam radiation therapy *: Wlicoxon singed-rank test
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occur due to the migrated seeds.
In this study, seed migration to sites other than the
lungs was observed in 10.5 % of the patients. In several
previous reports, only seed migration to the chest was
assessed, whereas few have studied seed migration to
sites other than the lungs [9] (Table 4). Seeds may
migrate to sites other than the lungs in approximately
5.4–11 % of the cases; thus, not only chest radiography
(PA + lateral views) but also abdominal radiography
should be performed simultaneously to accurately assess
the seed migration incidence after PI [29]. Moreover,
there is a report describing that the seed migration sites
were confirmed by scintigraphy [8].
In the present study, we divided patients into the PI
and PI + EBRT groups for analysis, finding that the seed
migration incidence was higher in the PI group than inthe PI + EBRT group (Table 1). This is the first report of
a comparison between the PI and PI + EBRT groups.
Moreover, within the PI group, the prostate volume
and the number of implanted seeds were significantly
larger in patients with seed migration (Table 1). Some of
the past studies also revealed that the number of im-
planted seeds is associated with the seed migration inci-
dence [9, 24].
Furthermore, in the present study, the seed migra-
tion incidence was significantly lower, as the time of
patient enrollment to cohort 1 of the J-POPS study
was later (Fig. 3). This is assumed to reflect the
effects of the learning curve through the accumula-
tion of experience in the treatment procedure.
Taussky et al. have also reported that the seed mi-
gration incidence was reduced as the learning curve
increased [7].
Fig. 2 Seed migration rates of each chest X-P methods. PI = permanent iodine-125 seed implantation; PI + EBRT = PI combined with external
beam radiation therapy; PA = posterior-anterior *: Chi square test
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Because there are cases in which seed migration is not
detected on the day of or after PI, but can be confirmed
one month later, the seed migration incidence has often
been reported to be higher at one month or more after
implantation than on the following day [8, 10, 18, 20,
22]. Moreover, migrating seeds that are located in the
pelvic cavity on the day after implantation may migrate
to the lungs one month later [29]. Based on these re-
ports, if the presence or absence of seed migration is
checked only on the day of or after seed implantation,
seed migration may be underestimated. Sugawara et al.
have reported that the proportions of patients withFig. 3 Seed migration rates according to the number of years registered in J-
Iodine-125 Seed Implantation; PI = permanent iodine-125 seed implanta
*: Chi square testconfirmed seed migration were 13.9 % on the day after
implantation, 22.8 % at 14 days after implantation, and
23.6 % at 3 months after implantation, showing an in-
crease over time [18]. When loose seeds are used, the
probability of new seed migration occurring one month
or more after implantation is extremely low, and it
seems appropriate to check seed migration one to three
months after implantation instead of immediately after
implantation [27]. In the present study, because patients
with seed migration that was confirmed one to three
months after implantation accounted for 88.6 %, seed
migration was evaluated during the appropriate period
in the majority of the patients. Although no difference inPOPS. J-POPS = Japanese Prostate Cancer Outcome Study of Permanent
tion; PI + EBRT = PI combined with external beam radiation therapy
Table 4 Seed migration literature review
Percentage of patients with migration




Isotope Lung Others Lung + Others Percentage of total seeds Time of checking for
migration
Grimm et al. [21] 1993 221 221/0 I-125/Pd-103 (loose) 17.6 - - - Day 1
Nag et al. [22] 1997 107 107/0 Pd-103 (loose) 17.8 - - 0.3 (lung) 1 month
Tapen et al. [23] 1998 289 244/45 I-125/Pd-103 (loose,
linked)
5.9 (loose 11.0, linked
0.7 )
- - - Day 1
Merrick et al. [10] 2000 175 73/102 I-125/Pd-103 (loose,
linked)
21.8 (loose 22.2, linked
21.4)
- - 0.22 (lung) <14 days, or >30 days
Older et al. [11] 2001 110 110/0 Pd-103 (loose) 29.0 - - - 1-16 months




2004 100 100/0 I-125/Pd-103 (loose) 55.0 - - 0.98 (lung) 2-3 months
Chauveinc et al.
[25]
2004 170 170/0 I-125 (loose) 16.0 - - 0.26 (lung) 2 months
Kunos et al. [26] 2004 120 120/0 I-125/Pd-103 (loose) 43.0 - - 0.54 (lung), 0.33 (pelvis) Median 133 days
Fueller et al. [20] 2004 37 37/0 I-125/Pd-103 (loose) 24.0 5.4 - 0.193 (lung), 0.035 (pelvis) 3-12 months
23 23/0 I-125/Pd-103 (linked) 0 0 - 0 3-12 months
Stone et al. [12] 2005 238 199/39 I-125/Pd103 1.7 - - - Median 30 months
Saibishkumar
et al. [13]
2009 20 20/0 I-125 (loose) 20.0 - - 0.23 1 month
20 20/0 I-125 (linked) 0 - - 0 1 month
Kono et al. [8] 2010 62 62/0 I-125 (loose) - - 69.4 0.87 (lung), 1.4




2011 267 265/2 I-125 (loose) 22.2 7.9 - 0.36 (lung), 0.11
(abdomen + pelvis)
Median 41 months
Taussky et al. [7] 2012 495 495/0 I-125 (loose) 10.3 - 22.8 0.26 (lung), 0.58 (lung + others) 1 month
Miyazawa et al.
[29]





2014 66 66/0 I-125 (loose) 30.0 39.3
(abdominopelvis)
52* - 1 month
74 74/0 I-125 (linked) 0 0 0 - 1 month
J-POPS 2015 1641 1641/0 I-125 (loose) 14.6 11.1 22.7 0.49 (lung+others) Day 1 to 3 months
519 0/519 I-125 (loose) 11.2 8.5 18.1 0.53 (lung+others) Day 1 to 3 months
*: Include lung, abdominopelvis, seminal vesicle and seed positioned more than 1cm from other seeds
I-125 = idodine-125; Pd-103 = palladium-103; J-POPS = Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation
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tients with seed migration confirmed on Day 1 and those
with seed migration confirmed at one to three months
after implantation, the incidence might have been under-
estimated in the former cases.
Adverse events associated with seed migration
The previously reported serious complications of migrat-
ing seeds include pneumonia [34], small cell lung cancer
[35], myocardial infarction caused by seeds migrating
into the coronary arteries [36], and neurological symp-
toms in the left lower extremity [37]. In the cases of mi-
gration into the coronary arteries, it is assumed that a
right-to-left atrial or ventricular shunt existed [36]. The
present study revealed no difference in adverse events
(urination and gastrointestinal symptoms) according to
the presence or absence of migrating seeds during the
follow-up period, and no adverse events were observed
at the sites of seed migration. Although the probability
of occurrence of serious complications of seed migration
can be expected to be extremely low, careful follow-up
observation needs to be continued further in order to
determine the presence or absence of an impact at the
sites of seed migration.
Impact on radiation doses
Many of the past reports describe that there was no
difference in D90 (Gy) values regardless of the pres-
ence or absence of seed migration [9, 23], whereas
there are also reports that, with a large number of
migrating seeds, V100 (%) and D90 (%) values tended
to decrease [38–40]. In the present study, no impact
on D90 (Gy) values was observed regardless of the
presence or absence of seed migration (Table 3).
However, when patients were divided into three
groups of those without seed migration, with one mi-
grating seed, and with two or more migrating seeds,
the D90 (Gy) and V100 (%) values in the patients
with two or more migrating seeds were significantly
lower than that in patients without seed migration
(Fig. 1). Despite the significant differences in D90
(Gy) values, the differences in the radiation doses
were extremely small, and all three groups were ex-
posed, on average, to the prescribed radiation doses
or more. Thus, we assume that the impact on the
treatment outcomes was small. However, if more
seeds migrate, radiation doses will be insufficient, and
treatment outcomes may be affected [40]. When in-
sufficient radiation dose due to seed migration is ap-
parent, reimplantation to the target site should be
considered [41].
When loose seeds are used, implanting peripheral
seeds within the prostate instead of the extraprostatic
area is important to reduce seed migration [12, 23].Comparison between loose seeds and linked seeds
Methods to reduce seed migration include the implant-
ation of seeds in the capsule and the use of linked seeds.
The incidence of migration of linked seeds reportedly
ranges from 0 % to 35 %, which is lower than that of
loose seeds [13, 23, 38, 42] (Table 4). Because linked
seeds could not be used in Japan during the enrollment
period of the J-POPS study, the seed migration incidence
during this period cannot be compared between loose
and linked seeds. In Japan, linked seeds became available
in 2013, and since that time, there is a report that the in-
cidence of the migration of linked seeds was lower than
that of loose seeds [42]. With regards to radiation dose
calculations, some reports describe that D90 (Gy) values
were higher for linked seeds than for loose seeds [20, 39,
43], whereas other reports describe that no difference
was observed [38, 42, 44, 45]. The opinions are divided.
There is also another report that, although differences in
D90 (Gy) values were observed between linked and loose
seeds, no difference was observed in the seven-year
recurrence-free rates based on prostate-specific antigen
analysis [46]. Even if radiation doses are affected by the
use of linked seeds, the impact on treatment outcomes
can be expected to be extremely small. It has been re-
ported that 30 days after treatment with linked seeds, a
strand of four linked seeds migrated into the pelvic cav-
ity [28], and that a strand of five linked seeds migrated
out from the prostate 30 days after PI [31]. Even linked
seeds may migrate into the veins. If linked seeds migrate
as a strand, seeds implanted in the tract will migrate out
from the prostate at one time, and there may be sub-
stantial impact on radiation doses. Moreover, linked
seeds implanted in the extracapsular area may migrate
when the vicryl sutures or spacers to which the seeds
are attached are dissolved and absorbed. Thus, even if
seed migration is evaluated on the day of implantation
or one to three months after implantation, migration
may not have yet occurred. When linked seeds are used,
it should be considered to evaluate seed migration at a
later time than when loose seeds are used [10, 12]. In
clinical practice, when surgeons with techniques to im-
plant loose seeds within the prostate perform implant-
ation, the number of migrating seeds is two seeds or
fewer in the majority of the cases, and the impact on
D90 (Gy) values is small. However, further long-term
follow-up studies are necessary to determine whether
seed migration affects treatment outcomes.
Limitation
In the present multi-institutional study, implantation
was usually performed by a different urologist for each
facility, and treatment planning was usually conducted
by a different radiologist for each facility. Because of the
differences among the facilities in terms of the treatment
Nakano et al. Radiation Oncology  (2015) 10:228 Page 11 of 12experience of the doctors, radiation dose calculation
software, prescribed radiation doses, methods to evaluate
seed migration, methods to implant seeds, time of evalu-
ating seed migration, the seed migration incidence varies
among the facilities and may be underestimated.
Despite the limitations described above, the results of
the present study appear to reflect the current state of
the seed migration incidence after treatment with I-125
loose seeds in Japan.
However, because this study had a short follow-up
period, long-term follow-up observation is needed in the
future to investigate whether adverse events occur at
sites of seed migration or how treatment outcomes are
affected.Conclusions
The seed migration incidence was 21.6 % (PI: 22.7 %,
PI + EBRT: 18.1 %), and it was higher in the PI group.
In the PI group, the seed migration incidence was
higher in those patients with a larger number of implanted
seeds. Although there was no difference in D90 (Gy) and
V100 (%) values between patients with and without seed
migration in the both PI and PI + EBRT groups, the V150
(%), UD90 (Gy), and UD5 (Gy) values were significantly
lower in patients with seed migration in the PI group.
Thus, when the number of migrating seeds is large, radi-
ation doses may be affected. Moreover, because migration
to sites other than the lungs was observed in 10.5 % (PI:
11.1 %, PI + EBRT: 8.5 %), but also abdominal or pelvic
radiography as well as chest radiography should be per-
formed to check for seed migration. Additionally, patients
who receive PI should be provided with a sufficient ex-
planation of the possible seed migration before treatment.
To the best of our knowledge, this is the first reported
prospective cohort study on I-125 loose seed migration,
and investigates a record number of cases. It is also the
first report to compare the incidence of migration be-
tween a PI group and a PI + EBRT group.
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